Hypoglycemic Agents

DRUG3 trials

Sponsors

Tanaka Masami, Kaneto Hideaki, National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Diabetic RetinopathyType 2 Diabetes Mellitus Diabetes Mellitus, Type 2Type 2 diabetes mellitus Diabetes Mellitus, Type 2

Phase 3

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

CompletedNCT00542178

National Heart, Lung, and Blood Institute (NHLBI)Diabetic Retinopathy

Start: 2003-10-31End: 2009-12-31Updated: 2018-07-24

Unknown Phase

The Study of Effect of antidiabetic agents on pancreatic beta-Cell REsponsiveness To glucose; comparative Evaluation of DPP-4 Inhibitors and SGLT2 inhibitor, Luseogliflozin

Active, not recruitingJPRN-jRCTs061190008

Kaneto HideakiType 2 Diabetes Mellitus Diabetes Mellitus, Type 2

Start: 2019-07-10Target: 114Updated: 2025-07-18

RESTORE-nephropathy study

Active, not recruitingJPRN-jRCTs031190185

Tanaka MasamiType 2 diabetes mellitus Diabetes Mellitus, Type 2

Start: 2020-01-14Target: 47Updated: 2025-07-18

Related Papers

Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study)

Frontiers in Endocrinology2024-10-212 citations

886-P: Protective Effects of DPP-4 Inhibitor and SGLT2 Inhibitor on Pancreatic ß-Cell Function—Randomized, Parallel-Group, Multicenter, Open-Label Study (SECRETE-I)

Diabetes2023-06-20

Effects of medical therapies on retinopathy progression in type 2 diabetes.

2010-06-29850 citations

Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.

2010-03-0138 citations